Cargando…
_version_ 1785038210579038208
author Jeon, Ah-Jung
Anene-Nzelu, Chukwuemeka George
Teo, Yue-Yang
Chong, Shay Lee
Sekar, Karthik
Wu, Lingyan
Chew, Sin-Chi
Chen, Jianbin
Kendarsari, Raden Indah
Lai, Hannah
Ling, Wen Huan
Kaya, Neslihan Arife
Lim, Jia Qi
Chung, Alexander Yaw Fui
Cheow, Peng-Chung
Kam, Juinn Huar
Madhavan, Krishnakumar
Kow, Alfred
Ganpathi, Iyer Shridhar
Lim, Tony Kiat Hon
Leow, Wei-Qiang
Loong, Shihleone
Loh, Tracy Jiezhen
Wan, Wei Keat
Soon, Gwyneth Shook Ting
Pang, Yin Huei
Yoong, Boon Koon
Bee-Lan Ong, Diana
Lim, Jasmine
de Villa, Vanessa H.
dela Cruz, Rouchelle D.
Chanwat, Rawisak
Thammasiri, Jidapa
Bonney, Glenn K.
Goh, Brian K.P.
Foo, Roger Sik Yin
Chow, Pierce Kah-Hoe
author_facet Jeon, Ah-Jung
Anene-Nzelu, Chukwuemeka George
Teo, Yue-Yang
Chong, Shay Lee
Sekar, Karthik
Wu, Lingyan
Chew, Sin-Chi
Chen, Jianbin
Kendarsari, Raden Indah
Lai, Hannah
Ling, Wen Huan
Kaya, Neslihan Arife
Lim, Jia Qi
Chung, Alexander Yaw Fui
Cheow, Peng-Chung
Kam, Juinn Huar
Madhavan, Krishnakumar
Kow, Alfred
Ganpathi, Iyer Shridhar
Lim, Tony Kiat Hon
Leow, Wei-Qiang
Loong, Shihleone
Loh, Tracy Jiezhen
Wan, Wei Keat
Soon, Gwyneth Shook Ting
Pang, Yin Huei
Yoong, Boon Koon
Bee-Lan Ong, Diana
Lim, Jasmine
de Villa, Vanessa H.
dela Cruz, Rouchelle D.
Chanwat, Rawisak
Thammasiri, Jidapa
Bonney, Glenn K.
Goh, Brian K.P.
Foo, Roger Sik Yin
Chow, Pierce Kah-Hoe
author_sort Jeon, Ah-Jung
collection PubMed
description BACKGROUND & AIMS: Lifestyle and environmental-related exposures are important risk factors for hepatocellular carcinoma (HCC), suggesting that epigenetic dysregulation significantly underpins HCC. We profiled 30 surgically resected tumours and the matched adjacent normal tissues to understand the aberrant epigenetic events associated with HCC. METHODS: We identified tumour differential enhancers and the associated genes by analysing H3K27 acetylation (H3K27ac) chromatin immunoprecipitation sequencing (ChIP-seq) and Hi-C/HiChIP data from the resected tumour samples of 30 patients with early-stage HCC. This epigenome dataset was analysed with previously reported genome and transcriptome data of the overlapping group of patients from the same cohort. We performed patient-specific differential expression testing using multiregion sequencing data to identify genes that undergo both enhancer and gene expression changes. Based on the genes selected, we identified two patient groups and performed a recurrence-free survival analysis. RESULTS: We observed large-scale changes in the enhancer distribution between HCC tumours and the adjacent normal samples. Many of the gain-in-tumour enhancers showed corresponding upregulation of the associated genes and vice versa, but much of the enhancer and gene expression changes were patient-specific. A subset of the upregulated genes was activated in a subgroup of patients’ tumours. Recurrence-free survival analysis revealed that the patients with a more robust upregulation of those genes showed a worse prognosis. CONCLUSIONS: We report the genomic enhancer signature associated with differential prognosis in HCC. Findings that cohere with oncofoetal reprogramming in HCC were underpinned by genome-wide enhancer rewiring. Our results present the epigenetic changes in HCC that offer the rational selection of epigenetic-driven gene targets for therapeutic intervention or disease prognostication in HCC. IMPACT AND IMPLICATIONS: Lifestyle and environmental-related exposures are the important risk factors of hepatocellular carcinoma (HCC), suggesting that tumour-associated epigenetic dysregulations may significantly underpin HCC. We profiled tumour tissues and their matched normal from 30 patients with early-stage HCC to study the dysregulated epigenetic changes associated with HCC. By also analysing the patients’ RNA-seq and clinical data, we found the signature genes – with epigenetic and transcriptomic dysregulation – associated with worse prognosis. Our findings suggest that systemic approaches are needed to consider the surrounding cellular environmental and epigenetic changes in HCC tumours.
format Online
Article
Text
id pubmed-10165154
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-101651542023-05-09 A genomic enhancer signature associates with hepatocellular carcinoma prognosis Jeon, Ah-Jung Anene-Nzelu, Chukwuemeka George Teo, Yue-Yang Chong, Shay Lee Sekar, Karthik Wu, Lingyan Chew, Sin-Chi Chen, Jianbin Kendarsari, Raden Indah Lai, Hannah Ling, Wen Huan Kaya, Neslihan Arife Lim, Jia Qi Chung, Alexander Yaw Fui Cheow, Peng-Chung Kam, Juinn Huar Madhavan, Krishnakumar Kow, Alfred Ganpathi, Iyer Shridhar Lim, Tony Kiat Hon Leow, Wei-Qiang Loong, Shihleone Loh, Tracy Jiezhen Wan, Wei Keat Soon, Gwyneth Shook Ting Pang, Yin Huei Yoong, Boon Koon Bee-Lan Ong, Diana Lim, Jasmine de Villa, Vanessa H. dela Cruz, Rouchelle D. Chanwat, Rawisak Thammasiri, Jidapa Bonney, Glenn K. Goh, Brian K.P. Foo, Roger Sik Yin Chow, Pierce Kah-Hoe JHEP Rep Research Article BACKGROUND & AIMS: Lifestyle and environmental-related exposures are important risk factors for hepatocellular carcinoma (HCC), suggesting that epigenetic dysregulation significantly underpins HCC. We profiled 30 surgically resected tumours and the matched adjacent normal tissues to understand the aberrant epigenetic events associated with HCC. METHODS: We identified tumour differential enhancers and the associated genes by analysing H3K27 acetylation (H3K27ac) chromatin immunoprecipitation sequencing (ChIP-seq) and Hi-C/HiChIP data from the resected tumour samples of 30 patients with early-stage HCC. This epigenome dataset was analysed with previously reported genome and transcriptome data of the overlapping group of patients from the same cohort. We performed patient-specific differential expression testing using multiregion sequencing data to identify genes that undergo both enhancer and gene expression changes. Based on the genes selected, we identified two patient groups and performed a recurrence-free survival analysis. RESULTS: We observed large-scale changes in the enhancer distribution between HCC tumours and the adjacent normal samples. Many of the gain-in-tumour enhancers showed corresponding upregulation of the associated genes and vice versa, but much of the enhancer and gene expression changes were patient-specific. A subset of the upregulated genes was activated in a subgroup of patients’ tumours. Recurrence-free survival analysis revealed that the patients with a more robust upregulation of those genes showed a worse prognosis. CONCLUSIONS: We report the genomic enhancer signature associated with differential prognosis in HCC. Findings that cohere with oncofoetal reprogramming in HCC were underpinned by genome-wide enhancer rewiring. Our results present the epigenetic changes in HCC that offer the rational selection of epigenetic-driven gene targets for therapeutic intervention or disease prognostication in HCC. IMPACT AND IMPLICATIONS: Lifestyle and environmental-related exposures are the important risk factors of hepatocellular carcinoma (HCC), suggesting that tumour-associated epigenetic dysregulations may significantly underpin HCC. We profiled tumour tissues and their matched normal from 30 patients with early-stage HCC to study the dysregulated epigenetic changes associated with HCC. By also analysing the patients’ RNA-seq and clinical data, we found the signature genes – with epigenetic and transcriptomic dysregulation – associated with worse prognosis. Our findings suggest that systemic approaches are needed to consider the surrounding cellular environmental and epigenetic changes in HCC tumours. Elsevier 2023-02-26 /pmc/articles/PMC10165154/ /pubmed/37168287 http://dx.doi.org/10.1016/j.jhepr.2023.100715 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Jeon, Ah-Jung
Anene-Nzelu, Chukwuemeka George
Teo, Yue-Yang
Chong, Shay Lee
Sekar, Karthik
Wu, Lingyan
Chew, Sin-Chi
Chen, Jianbin
Kendarsari, Raden Indah
Lai, Hannah
Ling, Wen Huan
Kaya, Neslihan Arife
Lim, Jia Qi
Chung, Alexander Yaw Fui
Cheow, Peng-Chung
Kam, Juinn Huar
Madhavan, Krishnakumar
Kow, Alfred
Ganpathi, Iyer Shridhar
Lim, Tony Kiat Hon
Leow, Wei-Qiang
Loong, Shihleone
Loh, Tracy Jiezhen
Wan, Wei Keat
Soon, Gwyneth Shook Ting
Pang, Yin Huei
Yoong, Boon Koon
Bee-Lan Ong, Diana
Lim, Jasmine
de Villa, Vanessa H.
dela Cruz, Rouchelle D.
Chanwat, Rawisak
Thammasiri, Jidapa
Bonney, Glenn K.
Goh, Brian K.P.
Foo, Roger Sik Yin
Chow, Pierce Kah-Hoe
A genomic enhancer signature associates with hepatocellular carcinoma prognosis
title A genomic enhancer signature associates with hepatocellular carcinoma prognosis
title_full A genomic enhancer signature associates with hepatocellular carcinoma prognosis
title_fullStr A genomic enhancer signature associates with hepatocellular carcinoma prognosis
title_full_unstemmed A genomic enhancer signature associates with hepatocellular carcinoma prognosis
title_short A genomic enhancer signature associates with hepatocellular carcinoma prognosis
title_sort genomic enhancer signature associates with hepatocellular carcinoma prognosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165154/
https://www.ncbi.nlm.nih.gov/pubmed/37168287
http://dx.doi.org/10.1016/j.jhepr.2023.100715
work_keys_str_mv AT jeonahjung agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT anenenzeluchukwuemekageorge agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT teoyueyang agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT chongshaylee agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT sekarkarthik agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT wulingyan agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT chewsinchi agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT chenjianbin agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT kendarsariradenindah agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT laihannah agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT lingwenhuan agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT kayaneslihanarife agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT limjiaqi agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT chungalexanderyawfui agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT cheowpengchung agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT kamjuinnhuar agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT madhavankrishnakumar agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT kowalfred agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT ganpathiiyershridhar agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT limtonykiathon agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT leowweiqiang agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT loongshihleone agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT lohtracyjiezhen agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT wanweikeat agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT soongwynethshookting agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT pangyinhuei agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT yoongboonkoon agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT beelanongdiana agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT limjasmine agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT devillavanessah agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT delacruzrouchelled agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT chanwatrawisak agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT thammasirijidapa agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT bonneyglennk agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT gohbriankp agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT foorogersikyin agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT chowpiercekahhoe agenomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT jeonahjung genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT anenenzeluchukwuemekageorge genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT teoyueyang genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT chongshaylee genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT sekarkarthik genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT wulingyan genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT chewsinchi genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT chenjianbin genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT kendarsariradenindah genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT laihannah genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT lingwenhuan genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT kayaneslihanarife genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT limjiaqi genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT chungalexanderyawfui genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT cheowpengchung genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT kamjuinnhuar genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT madhavankrishnakumar genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT kowalfred genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT ganpathiiyershridhar genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT limtonykiathon genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT leowweiqiang genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT loongshihleone genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT lohtracyjiezhen genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT wanweikeat genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT soongwynethshookting genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT pangyinhuei genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT yoongboonkoon genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT beelanongdiana genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT limjasmine genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT devillavanessah genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT delacruzrouchelled genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT chanwatrawisak genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT thammasirijidapa genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT bonneyglennk genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT gohbriankp genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT foorogersikyin genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis
AT chowpiercekahhoe genomicenhancersignatureassociateswithhepatocellularcarcinomaprognosis